{"nctId":"NCT02573883","briefTitle":"Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus","startDateStruct":{"date":"2015-10"},"conditions":["Vulvar Lichen Sclerosus"],"count":52,"armGroups":[{"label":"Prior Clobetasol Exposure","type":"EXPERIMENTAL","interventionNames":["Device: Fractionated Carbon Dioxide Laser","Drug: Clobetasol Propionate 0.05% ointment"]},{"label":"No Prior Clobetasol Exposure","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Fractionated Carbon Dioxide Laser","Drug: Clobetasol Propionate 0.05% ointment"]}],"interventions":[{"name":"Fractionated Carbon Dioxide Laser","otherNames":["SmartXide -V2-LR system","Mona Lisa Laser"]},{"name":"Clobetasol Propionate 0.05% ointment","otherNames":["Temovate Propionate 0.05% ointment"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Biopsy proven symptomatic vulvar lichen sclerosus\n* Ability to understand the study, accept randomization and logistically follow-up with scheduled visits\n* English Speaking\n\nExclusion Criteria:\n\n* Known vulvar malignancy\n* Pregnancy or planning pregnancy or less than 3 months postpartum\n* Premenopausal\n* Current or prior diagnosis of any gynecologic malignancy\n* Previous pelvic radiation therapy\n* Allergy to topical steroid\n* Active Urinary Tract Infection (UTI), vulvar infection (candida, herpes, bacterial vaginosis, trichomoniasis or other infection)\n* Pelvic organ prolapse \\> than Stage 2\n* Treatment with systemic immunomodulators, topical calcineurin inhibitors (tacrolimus, pimecrolimus), or vaginal hormonal or vulvar topical steroid use within 2 months of enrollment\n* History of transvaginal mesh implant (excluding sling or sacrocolpopexy mesh)\n* IUD (Intrauterine Device)\n* Skindex-29 overall score \\<21, below mildly impaired health related quality of life threshold","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in SkinDEX-29 Score","description":"The Skindex-29 is a validated questionnaire for assessing acute dermatologic symptoms over a 4-week period. The Skindex-29 is a 29 question version of the original SkinDEX questionnaire. Total numeric score is reported ranging from 0-100. Scores reported as a change between six months and baseline with more negative scores indicating greater improvement in symptoms (better outcome).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.83","spread":"18.09"},{"groupId":"OG001","value":"-5.92","spread":"5.81"}]}]}]},{"type":"SECONDARY","title":"Change in Subjective Vulvovaginal Symptoms Questionnaire (VSQ)","description":"Subjective measure of vulvar symptoms of itching, burning, dyspareunia of Lichen Sclerosus. VSQ is a 21-item instrument and scores range from 0 to 20 with increased scores indicating increased vulvovaginal symptom bother. The change in VSQ is reported with more negative scores indicating greater improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.92","spread":"4.12"},{"groupId":"OG001","value":"-0.58","spread":"5.11"}]}]}]},{"type":"SECONDARY","title":"Change in Subjective Vulvovaginal Symptoms Questionnaire (VSQ)","description":"Subjective measure of vulvar symptoms of itching, burning, dyspareunia of Lichen Sclerosus. VSQ is a 21-item instrument and scores range from 0 to 20 with increased scores indicating increased vulvovaginal symptom bother. The change in VSQ is reported with more negative scores indicating greater improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"4.43"},{"groupId":"OG001","value":"0.3","spread":"2.41"},{"groupId":"OG002","value":"-1.82","spread":"3.66"},{"groupId":"OG003","value":"-2.9","spread":"3.98"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Considered Satisfied as Assessed by Health Related Quality of Life (HRQOL) Score","description":"Patient global impression of satisfaction total score on visual analog scale (very satisfied or satisfied) ranging from 1-5 with higher scores indicating greater satisfaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Considered Satisfied as Assessed by Health Related Quality of Life (HRQOL) Score","description":"Patient global impression of satisfaction total score on visual analog scale (very satisfied or satisfied) ranging from 1-5 with higher scores indicating greater satisfaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change Vaginal Health Index (VHI) Score","description":"The Vaginal Health Index is a five item scale with scores ranging from 5-25 with lower scores indicating greater urogenital atrophy. The change in VHI is express with more negative scores indicating greater improvement between study time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"4.34"},{"groupId":"OG001","value":"-0.43","spread":"3.62"}]}]}]},{"type":"SECONDARY","title":"Change Vaginal Health Index (VHI) Score","description":"The Vaginal Health Index is a five item scale with scores ranging from 5-25 with lower scores indicating greater urogenital atrophy. The change in VHI is express with more negative scores indicating greater improvement between study time points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.86","spread":"4.37"},{"groupId":"OG001","value":"1.44","spread":"4.45"},{"groupId":"OG002","value":"1.73","spread":"2.83"},{"groupId":"OG003","value":"1.3","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"Change Vulvar Symptom Visual Analog Scale (VAS) Score","description":"Patient subjective scale of symptoms of Lichen Sclerosus. Each item scaled 0-10 with greater severity of symptoms indicated by higher score. Results expressed as change with more negative values indicating greater improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.26","spread":"3.75"},{"groupId":"OG001","value":"-1.83","spread":"2.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.78","spread":"3.76"},{"groupId":"OG001","value":"-1.00","spread":"3.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.15","spread":"4.04"},{"groupId":"OG001","value":"-1.32","spread":"2.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"2.95"},{"groupId":"OG001","value":"-0.14","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.77","spread":"3.55"},{"groupId":"OG001","value":"-1.32","spread":"4.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.11","spread":"3.47"},{"groupId":"OG001","value":"-0.78","spread":"2.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"2.83"},{"groupId":"OG001","value":"-0.78","spread":"2.67"}]}]}]},{"type":"SECONDARY","title":"Change Vulvar Symptom Visual Analog Scale (VAS) Score","description":"Patient subjective scale of symptoms of Lichen Sclerosus. Each item scaled 0-10 with greater severity of symptoms indicated by higher score. Results expressed as change with more negative values indicating greater improvement in symptoms (better outcome).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"3.76"},{"groupId":"OG001","value":"-0.1","spread":"3.03"},{"groupId":"OG002","value":"-1.82","spread":"3.06"},{"groupId":"OG003","value":"0.89","spread":"4.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"3.43"},{"groupId":"OG001","value":"-1.5","spread":"3.87"},{"groupId":"OG002","value":"-0.73","spread":"4.45"},{"groupId":"OG003","value":"-0.9","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"4.03"},{"groupId":"OG001","value":"-1","spread":"3.54"},{"groupId":"OG002","value":"-1.64","spread":"2.69"},{"groupId":"OG003","value":"0.67","spread":"3.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"4.26"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"-1.62","spread":"3.25"},{"groupId":"OG003","value":"-2","spread":"4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"3.8"},{"groupId":"OG001","value":"-0.8","spread":"2.66"},{"groupId":"OG002","value":"-2.12","spread":"3.14"},{"groupId":"OG003","value":"-0.22","spread":"1.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"4.77"},{"groupId":"OG001","value":"-0.2","spread":"3.97"},{"groupId":"OG002","value":"-1.27","spread":"2.94"},{"groupId":"OG003","value":"-0.4","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"3.21"},{"groupId":"OG001","value":"-0.57","spread":"3.98"},{"groupId":"OG002","value":"-0.09","spread":"1.38"},{"groupId":"OG003","value":"-0.89","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Change SkinDEX-29 Score","description":"The Skindex-29 is a validated questionnaire for assessing acute dermatologic symptoms over a 4-week period. The Skindex-29 is a 29 question version of the original SkinDEX questionnaire. Total numeric score is reported ranging from 0-100. Scores reported as a change between six months and baseline with more negative scores indicating greater improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"25.94"},{"groupId":"OG001","value":"-7.05","spread":"22.13"},{"groupId":"OG002","value":"-10.23","spread":"17.53"},{"groupId":"OG003","value":"-1.52","spread":"11"}]}]}]},{"type":"SECONDARY","title":"Change Objective Provider VAS Visual Analog Scale","description":"Provider scored objective appearance of vulvar Lichen Sclerosus. Each item scaled 0-10 with greater severity of appearance indicated by higher score. Results expressed as change with more negative values indicating greater improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":"1.70"},{"groupId":"OG001","value":"-1.3","spread":"1.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.58","spread":"1.92"},{"groupId":"OG001","value":"-1.5","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"2.82"},{"groupId":"OG001","value":"-0.70","spread":"2.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"3.49"},{"groupId":"OG001","value":"-1.77","spread":"3.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"2.44"},{"groupId":"OG001","value":"-0.78","spread":"2.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.5"},{"groupId":"OG001","value":"0.35","spread":"2.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"2.3"},{"groupId":"OG001","value":"0.22","spread":"2.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.12","spread":"2.4"},{"groupId":"OG001","value":"-1.78","spread":"2.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"2.86"},{"groupId":"OG001","value":"-0.57","spread":"1.88"}]}]}]},{"type":"SECONDARY","title":"Change Objective Provider VAS Visual Analog Scale","description":"Provider scored objective appearance of vulvar Lichen Sclerosus. Each item scaled 0-10 with greater severity of appearance indicated by higher score. Results expressed as change with more negative values indicating greater improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"3.29"},{"groupId":"OG001","value":"-1.25","spread":"1.49"},{"groupId":"OG002","value":"-0.27","spread":"2.24"},{"groupId":"OG003","value":"-0.22","spread":"1.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"3.1"},{"groupId":"OG001","value":"0.38","spread":"1.6"},{"groupId":"OG002","value":"-0.45","spread":"1.81"},{"groupId":"OG003","value":"-0.2","spread":"1.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"2.6"},{"groupId":"OG001","value":"0.88","spread":"2.53"},{"groupId":"OG002","value":"-0.18","spread":"0.52"},{"groupId":"OG003","value":"-0.1","spread":"2.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"4.07"},{"groupId":"OG001","value":"0.29","spread":"1.7"},{"groupId":"OG002","value":"0.64","spread":"4.7"},{"groupId":"OG003","value":"-1.4","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"2.9"},{"groupId":"OG001","value":"-0.5","spread":"1.69"},{"groupId":"OG002","value":"0.73","spread":"2.8"},{"groupId":"OG003","value":"1.2","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"2.54"},{"groupId":"OG001","value":"-0.25","spread":"1.91"},{"groupId":"OG002","value":"-1.09","spread":"2.59"},{"groupId":"OG003","value":"-1","spread":"2.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"2.21"},{"groupId":"OG001","value":"-0.5","spread":"1.69"},{"groupId":"OG002","value":"-0.18","spread":"1.66"},{"groupId":"OG003","value":"0.2","spread":"2.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"2.53"},{"groupId":"OG001","value":"0.62","spread":"1.06"},{"groupId":"OG002","value":"-0.45","spread":"2.62"},{"groupId":"OG003","value":"-1.4","spread":"2.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"2.8"},{"groupId":"OG001","value":"0.12","spread":"0.35"},{"groupId":"OG002","value":"-0.36","spread":"1.03"},{"groupId":"OG003","value":"-0.6","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Outcomes","description":"Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Outcomes","description":"Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Outcomes","description":"Total number for adverse outcomes (of any severity) to include description of pain, infection, de novo or worsening dyspareunia, contact dermatitis and burns from treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["minor burning and blistering at treatment site","Activation Genital Herpes"]}}}